A flurry of deals suggests that drug firms favour buying their way out of trouble. Will face competition from cheaper copycats once key patents expire in 2028 in America and Europe two years later | Business
No comments yet. Be the first to comment!
More in Course Chunks from The Economist
No comments yet. Be the first to comment!